LINC01088/miR-22/CDC6 Axis Regulates Prostate Cancer Progression by Activating the PI3K/AKT Pathway

Figure 3

CDC6 targets miR-22 and reverses the effects of si-LINC01088 in PC3 and LNCAP cells. (a) Scatter plot shows differentially expressed mRNAs between the PCa and control groups. (b) The dual-luciferase reporter assay shows the relative luciferase activity of the CDC6-WT or CDC6-MUT plasmid between the miR-NC and miR-22 groups. (c) The disease-free survival rate was calculated in the CDC6-high or CDC6-low groups by TCGA survival analysis on the GEPIA2 database. (d) Relative expression levels of LINC01088 between the PCa tumor tissues and adjacent tissues. (e) Relative expression of LINC01088 in RWPE-2 and four PCa cell lines (C4-2, 22RV1, PC3, and LNCaP). (f) Dual-luciferase assay analysis of the binding of CDC6 to miR-22. (g) RT-qPCR analysis of the effect of si-LINC01088 on the expression of CDC6 in PC3 and LNCAP cells. (h) RT-qPCR verified the validity of overexpressing CDC6 plasmid. (i) RT-qPCR analysis of the reversal of LINC01088 expression by overexpressing CDC6 on si-LINC01088. .

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)